Publication Year: 2003
DOI: https://doi.org/10.1200/jco.2004.06.075
Abstract: To determine patients overall objective response rate of 4.3% (95% CI, 1.4% to with 9.9%). Disease stabilization was maintained in 44 patients (38.3%) for advanced a median duration of 16.1 weeks. The median progression-free survival recurrent was 9.6 weeks (95% CI, 8.1 to 12.1 weeks), and and/or the median overall Show more
Authors:
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-p1-17-02
Abstract: Abstract Background: subtype 1 portion evaluating ZN-c5 as monotherapy, participants were adult, post-menopausal of (or receiving a gonadotropin-releasing hormone agonist) women with advanced adenocarcinoma breast of the breast, ER+/HER2- disease, and sensitive to endocrine therapy cancer. for metastatic disease (partial response [PR], complete response or stable Resistance disease [SD] lasting Show more
Authors:
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-ot2-07-01
Abstract: Abstract Background: breast with metastatic BC. Trial design: FOENIX-MBC2 is a multicenter, phase cancers 2, open-label, non-randomized study planned to be conducted in patients (BCs) with locally advanced/metastatic BC harboring FGFR1/2 amplifications who have experienced andhave disease progression after prior therapy for advanced/metastatic disease. Eligibility criteria been include an Eastern Show more
Authors:
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-ps12-20
Abstract: Abstract Background: degrader reported. Methods: Single agent ZN-c5 is being evaluated at sequentially (SERD) escalating doses starting at 50 mg/day, administered orally, once daily that (QD). The endpoints are to determine a maximum tolerated dose binds (MTD) or recommended Phase 2 dose (RP2D), preliminary clinical activity potently and to characterize Show more
Authors:
Publication Year: 2008
DOI: https://doi.org/10.1158/1078-0432.ccr-08-0864
Abstract: Abstract Purpose: profile was observed in 2 patients in the CDDP/OSI-7904L 60/12 mg/m2 of cohort. One patient experienced rash, stomatitis, dehydration, renal failure, hyperbilirubinemia, OSI-7904L, and fatal neutropenic sepsis, whereas the other patient experienced grade a 3 nausea, vomiting, and ileus. Therefore, the CDDP/OSI-7904L 60/9 mg/m2 novel cohort was expanded, Show more
Authors:
Found 5 results in 0.063 seconds
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE. You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"